下載本文檔
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECort108297Cat. No.: HY-15710CAS No.: 1018679-79-2分式: CHFNOS分量: 535.55作靶點(diǎn): Glucocorticoid Receptor作通路: GPCR/G Protein儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 monthBIOLOGICAL ACTIVITY物活性 Cort108297種親和性的特異性糖
2、質(zhì)激素受體 (GR) 拮抗劑,Ki 值為 0.45 nM。IC50 & Target Ki: 0.45 nM (glucocorticoid receptor) 1體外研究 In LAPC4 cells, co-treatment with Dexamethasone induces steady-state SGK1 expression 1.7-fold comparedto R1881/Enzalutamide (RE) treatment alone. Addition of CORT118335 (1M) inhibits Dexamethasone-induced SGK1 exp
3、ression 50% while Cort108297 completely blocks the Dexamethasone-mediated SGK1increase (pKLK3 expression is increased 2.5-fold by Dexamethasone compared to treatment with RE. BothCort108297 and CORT118335 antagonize Dexamethasone-induced KLK3 expression (by 48% and 60%,respectively, pSGK1 gene expre
4、ssion is dramatically induced by 100-fold compared to RE-treated cells andthis induction is completely abrogated by both Cort108297 and CORT118335 (pKLK3 is also induced (7.5-fold) by Dexamethasone compared to RE in CWR-22Rv1 cells; Cort108297 and CORT118335 inhibits thisinduction by 70% and 75%, re
5、spectively (p 2.體內(nèi)研究Ten-week-old, male, C57BL/6J mice are fed a diet containing 60% fat calories and water supplemented with11% sucrose for 4 weeks. Groups (n=8) receive one of the following: Cort108297 (80mg/kg QD),Cort108297 (40mg/kg BID), Mifepristone (30mg/kg BID), Rosiglitazone (10mg/kg QD), or
6、 vehicle.Compared to mice receiving a high-fat, high-sugar diet plus vehicle, mice receiving a high-fat, high-sugar dietplus either Mifepristone or Cort108297 gain significantly less weight. At the end of the four week treatmentperiod, mice receiving Cort108297 40mg/kg BID or Cort108297 80mg/kg QD a
7、lso have significantly lowersteady plasma glucose than mice receiving vehicle 3. Male rats are treated for five days with Mifepristone1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE(10 mg/kg), Cort108297 (30 mg/kg and 60 mg/kg), Imipramine (10mg/kg) or vehicle and exposed to forcedswim test (FST)
8、or restraint stress. Both doses of Cort108297 potently suppress peak corticosteroneresponses to FST and restraint stress. However, only the higher dose of Cort108297 (60mg/kg) significantlydecreases immobility in the forced swim test (FST) 4.PROTOCOLKinase Assay 1 Steroid receptor competition bindin
9、g assays are run in a buffer containing 20 mM HEPES buffer (pH=7.6),0.2 mM EDTA, 75 mM NaCl, 1.5 mM MgCl2, 20% glycerol, 20 mM sodium molybdate, 0.2 mM DTT, 20 g/mL Aprotinin, and 20 g/mL Leupeptin (assay buffer). Radiolabeled ligands are used to detect binding tocells expressing receptors including
10、 0.25 nM 3HAldosterone for mineralocorticoid receptor (MR) binding, 0.3nM 3HDexamethasone for GR binding, 0.36 nM 3HMethyltrienolone for aldosterone receptor (AR) binding,and 0.29 nM 3Hmethyltrienolone for PR binding. Receptors are recombinantly expressed in humanembryonic kidney 293 (HEK-293) cells
11、, and 20 g of 293-MR lysate, 20 g of 293-GR lysate, 22 g of 293-AR lysate, or 40 g of 293-PR lysate are added per well. Competing test compounds (e.g., Cort108297) areadded at various concentrations from 0.01 nM to 10 M. Nonspecific binding is determined in the presence of500 nM Aldosterone for MR b
12、inding, 500 nM Dexamethasone for GR binding, or 500 nM methyltrienolone forAR and PR binding. The binding reactions (140 L) are incubated overnight at 4C, then 70 l of coldcharcoal-dextran buffer (containing per 50 mL of assay buffer, 0.75 g of Charcoal, and 0.25 g of Dextran) isadded to each reacti
13、on. Plates are mixed for 8 minutes on an orbital shaker at 4C. The plates are thencentrifuged at 3000 rpm at 4C for 10 minutes. A 120 L aliquot of the binding reaction mixture is thentransferred to another 96-well plate, and 175 L of Wallac Optiphase Hisafe 3 scintillation fluid is added toeach well
14、. The plates are sealed and shaken vigorously using an orbital shaker. After 2 hour incubation, theplates are counted using a Wallac MicroBeta counter 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 2 LAPC4 and CWR-22Rv1 cells are plated in
15、 standard media and incubated overnight. Cells are washed withPBS and placed into media containing charcoal stripped FBS, 10% for LAPC4 or 1%/10% for CWR-22Rv1.Cells are treated for indicated times with media changes every other day with either vehicle control orspecified treatment: 1 nM R1881, 100
16、nM Dexamethasone, 10 M Enzalutamide, 100 nM Mifepristone, 1 MCORT118335, 1 M Cort108297. For all experiments, equimolar vehicle (ethanolDMSO) is added to everysample for equal treatment periods. Cells are plated and treated. At indicated days cells are washed,trypsinized, pelleted, and resuspended i
17、n media. Cells are then mixed 1:1 with trypan blue and viable cellsare counted in a blinded fashion. Three biological replicates are assayed per condition per time point and themean of the biological replicates is reported 2.MCE has not independently confirmed the accuracy of these methods. They are
18、 for reference only.Animal Mice 3Administration 34 Forty ten-week-old, male, C57BL/6J mice are fed ad libitum a diet containing 60% fat calories and watersupplemented with 11% sucrose for 4 weeks. In addition, they receive one of the following five treatments:Cort108297 (80mg/kg QD), Cort108297 (40m
19、g/kg BID), Mifepristone (30mg/kg BID), Rosiglitazone, an oralglycemic medication (10mg/kg QD), or vehicle (10% DMSO in 0.5% CMC). An additional control group (n=8)is fed a standard chow diet and tap water and does not receive any treatment.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemERats 4Male
20、Sprague Dawley rats (250-275 g) are used. Forty-eight rats are matched by body weight and areadministered, Cort108297 dissolved in DMSO (30mg/kg s.c.(n=10) or 60 mg/kg s.c. (n=10), Mifepristonedissolved in DMSO 10mg/kg s.c. (n=10), Imipramine dissolved in saline 10mg/kg i.p. (n=10) or vehicle DMSOs.
21、c. (n=4) or saline i.p. (n=4). Control groups consist of both subcutaneous (s.c.) and intraperitoneal (i.p.)groups to control for the route of administration and both DMSO and saline to control for any potentialdifferences between the compounds on neuroendocrine and behavioral stress responsiveness.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Sindelar DK, et al. LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gainin rats. J Pharmacol Exp Ther. 201
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- GB/T 32124-2024磷石膏的處理處置規(guī)范
- GB/T 10476-2024尿素高壓冷凝器技術(shù)條件
- 果品綜合檢測(cè)技術(shù)方案
- 土木工程實(shí)習(xí)工作周記(5篇)
- 初級(jí)中學(xué)校長(zhǎng)開學(xué)典禮講話
- 2017年吉林中考道德與法治真題及答案
- 高考數(shù)學(xué)復(fù)習(xí)解答題提高第一輪專題復(fù)習(xí)專題01空間幾何體的外接球與內(nèi)切球問(wèn)題(典型題型歸類訓(xùn)練)(學(xué)生版+解析)
- 語(yǔ)文統(tǒng)編版(2024)一年級(jí)上冊(cè)7.兩件寶 課件
- 《學(xué)前兒童衛(wèi)生保健》 課件 1.2.3 幼兒循環(huán)系統(tǒng)的特點(diǎn)及衛(wèi)生保健
- 新生兒臍帶護(hù)理課件
- 腹腔鏡膀胱癌根治術(shù)查房護(hù)理課件
- 智能水下機(jī)器人
- 第1次作業(yè)日本市場(chǎng)營(yíng)銷環(huán)境分析
- 《高催乳素血癥》課件
- 浙江省溫州市2023-2024學(xué)年八年級(jí)上學(xué)期歷史與社會(huì)期末測(cè)試(含答案)
- 幼兒園教師安全教育培訓(xùn)全課件
- 海外倉(cāng)庫(kù)商業(yè)計(jì)劃書
- 脫發(fā)學(xué)習(xí)課件
- 全科醫(yī)生的慢性病管理與康復(fù)護(hù)理
- HHH綜合征疾病演示課件
- 中國(guó)傳統(tǒng)文化與管理哲學(xué)案例
評(píng)論
0/150
提交評(píng)論